DRRX — Stock Film
STOCK FILMSCENE 1/11DRRX · $1.91
Stock Expert AI presents
DRRX
DURECT Corporation
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
DURECT Corporation. A quick introduction.

On the stock market since 2000, it operates in the world of health and science. It has 21 employees. Now — the numbers.

on the stock market since 2000
21 employees
$59.3M market value
Revenue last year:
$0
The loss that same year:
$0
For every $1 it earns, the company spends $5.

The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.

WHERE DOES THE MONEY COME FROM?
93%Collaborative Research and Development and Other Revenue
Collaborative Research and Development and Other Revenue 93%Products 7%
93% of all revenue comes from a single line: Collaborative Research and Development and Other Revenue.

That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.

THE SALES TREND
Sales have been shrinking.

An average decline of 49% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.

$30.1M
2020
$14M
2021
$19.3M
2022
$8.5M
2023
$2M
2024
In the vault right now:
$0
DEBT: $2.2M
At this pace, that money lasts about 1.4 years.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 4 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Heavy investment in the future10/10
WEAK SPOTS
The stock has lost its spark0/10
Growth has stalled2/10
Costs eat into the margin4/10
WORTH WATCHING

Revenue Growth: Sales are growing slowly.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 93% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

THE BRIGHT SIDE

Nothing in the current numbers stands out as a strong positive. That, by itself, is worth knowing.

1
THE RISKS · 1/2
Small sales, big loss

A loss of $8.3M against $2.0M in annual sales. And on top of that, sales fell from the year before.

2
THE RISKS · 2/2
The cash has a countdown

At the current pace of spending, the cash lasts about 1.4 years. After that, the company needs to find new money.

FINALE · THE GRADE
C
0 / 100 · MoonshotScore

On our five-subject report card, DRRX sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.

The takeaway: DRRX is a small company that closed last year at a loss. The road back to profit runs through spending discipline.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Jul 21, 2026 · stockexpertai.com · Stock Film